Blood Podcast cover image

Prolonged response after stopping TPO-RA in ITP, TP53 mutations and myelofibrosis outcomes, clinical picture of ERCC6L2 disease, where variants predispose to marrow failure and malignancy

Blood Podcast

00:00

The Proportion of Sustained Complete Response to T-PoRA's at 24 and 52 Weeks After Treatment Cessation

This prospective multi-center interventional trial enrolled 49 ITP patients treated with T-PoRA's between September 2017 and February 2020 across 20 centers in France. Patients had either persistent or chronic primary ITP according to the international consensus criteria. After inclusion, the patients were weaned off El Trumbopag and Romi Plostum over 10 weeks. In the intention to treat analysis group, 56.2 percent of patients achieved a sustained response following discontinuation of T- PoRA's at week 24 and 52.1 percent at week 52.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app